Bone status in obese, non-diabetic, antipsychotic-treated patients, and effects of the glucagon-like peptide-1 receptor agonist exenatide on bone turnover markers and bone mineral density

HIGHLIGHTS

• who: Bjørn H. Ebdrup from the University of Naples Federico II, Italy have published the research work: Bone Status in Obese, Non-diabetic, Antipsychotic-Treated Patients, and Effects of the Glucagon-Like Peptide-1 Receptor Agonist Exenatide on Bone Turnover Markers and Bone Mineral Density, in the Journal: (JOURNAL)
• how: The authors compared baseline BTMs with the Danish Health 2006 study cohort as reference population and the authors calculated BMD T- and Z-scores. The authors a priori decided to repeat analyses after excluding patients with baseline values which could indicate pre-study disturbance . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.